Predictors of pulmonary tuberculosis treatment outcomes in South Korea: A prospective cohort study, 2005-2012

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Choi, Hongjo ^a,b   Lee, Myungsun ^a   Chen, Ray Y ^c   Kim, Youngran ^a   Yoon, Soyoung ^a   Joh, Joon S ^d   Park, Seung K ^e   Dodd, Lori E ^c   Lee, Jongseok ^a   Song, Taeksun ^a   Cai, Ying ^c   Goldfeder, Lisa C ^c   Via, Laura E ^c   Carroll, Matthew W ^c   Barry III, Clifton E ^c   Cho, Sang Nae ^a,f  

^a International Tuberculosis Research Center   (South Korea)

^b Korea University   (South Korea)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d National Medical Center   (South Korea)

^e National Masan Tuberculosis Hospital   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

Author keywords

Diabetes; Long term follow up; Multidrug resistant tuberculosis; South Korea; Tuberculosis; Unfavorable outcome

Indexed keywords

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; SOUTH KOREA; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; MIDDLE AGED; RISK FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

TUBERCULOSTATIC AGENT;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84903416990     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-360     Document Type: Article

References (26)

1. Snider DE, Roper WL. The New tuberculosis. N Engl J Med 1992, 326(10):703-705. 10.1056/NEJM199203053261011, 1736110.
2. WHO Global tuberculosis report 2013. WHO/HTM/TB/2013.11 2013, Geneva: World Health Organization, WHO.
3. World Health Organization The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis 2010, Geneva: World Health Organization, World Health Organization.
4. Gandy M, Zumla A. The resurgence of disease: social and historical perspectives on the 'new'tuberculosis. Soc Sci Med 2002, 55(3):385-396. 10.1016/S0277-9536(01)00176-9, 12144147.
5. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009, 68(12):2240-2246. 10.1016/j.socscimed.2009.03.041, 19394122.
6. Shetty N, Shemko M, Vaz M, D'Souza G. An epidemiological evaluation of risk factors for tuberculosis in South India: a matched case control study. Int J Tuberc Lung Dis 2006, 10(1):80-86.
7. Reed GW, Choi H, Lee SY, Lee M, Kim Y, Park H, Lee J, Zhan X, Kang H, Hwang S. Impact of Diabetes and Smoking on Mortality in Tuberculosis. PLoS One 2013, 8(2):e58044. 10.1371/journal.pone.0058044, 3585219, 23469139.
8. Kolappan C, Gopi PG. Tobacco smoking and pulmonary tuberculosis. Thorax 2002, 57(11):964-966. 10.1136/thorax.57.11.964, 1746222, 12403879.
9. Maciel EL, Brioschi AP, Peres RL, Guidoni LM, Ribeiro FK, Hadad DJ, Vinhas SA, Zandonade E, Palaci M, Dietze R, Johnson JL. Smoking and 2-month culture conversion during anti-tuberculosis treatment. Int J Tuberc Lung Dis 2013, 17(2):225-228. 10.5588/ijtld.12.0426, 23317958.
10. Franke M, Appleton S, Bayona J, Arteaga F, Palacios E, Llaro K, Shin S, Becerra M, Murray M, Mitnick C. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008, 46(12):1844-1851. 10.1086/588292, 2577177, 18462099.
11. Faustini A, Hall A, Perucci C. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006, 61(2):158. 10.1136/thx.2005.045963, 2104570, 16254056.
12. Kim H-R, Hwang SS, Kim HJ, Lee SM, Yoo C-G, Kim YW, Han SK, Shim Y-S, Yim J-J. Impact of extensive drug resistance on treatment outcomes in Non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007, 45(10):1290-1295. 10.1086/522537, 17968823.
13. Dalton T, Cegielski P, Akksilp S, Asencios L, Caoili JC, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012, 380(9851):1406-1417. 10.1016/S0140-6736(12)60734-X, 22938757.
14. Kim DH, Kim HJ, Park S-K, Kong S-J, Kim YS, Kim T-H, Kim EK, Lee KM, Lee SS, Park JS Koh WJ, Lee CH, Kim JY, Shim TS. Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis. Am J Respir Crit Care Med 2008, 178(10):1075-1082. 10.1164/rccm.200801-132OC, 18703792.
15. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, Enarson DA, Behr MA, van Helden PD. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005, 171(12):1430-1435. 10.1164/rccm.200409-1200OC, 15831840.
16. Millet JP, Shaw E, Orcau A, Casals M, Miro JM, Cayla JA, . Barcelona Tuberculosis Recurrence Working G Tuberculosis recurrence after completion treatment in a European city: reinfection or relapse?. PLoS One 2013, 8(6):e64898. 10.1371/journal.pone.0064898, 3679149, 23776440, Barcelona Tuberculosis Recurrence Working G.
17. World Health Organization Treatment of tuberculosis guidelines 4th edition 2010, Geneva: World Health Organization, World Health Organization.
18. KCDC Guideline for tuberculosis control, 2010 2010, Seoul: Korea Centers for Disease Control and Prevention (published in Korean), KCDC.
19. Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010, 14(4):454-463.
20. Jeon C, Hwang S, Min J, Prevots D, Goldfeder L, Lee H, Eum S, Jeon D, Kang H, Kim J. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008, 46(1):42-49. 10.1086/524017, 18171212.
21. Shin S, Pasechnikov A, Gelmanova I, Peremitin G, Strelis A, Andreev Y, Golubchikova V, Tonkel T, Yanova G, Nikiforov M. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006, 10(4):402-408.
22. Kwon Y, Kim Y, Suh G, Chung M, Kim H, Kwon OJ, Choi Y, Kim K, Kim J, Shim YM, Koh WJ. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clinical Infectious Diseases 2008, 47(4):496-502. 10.1086/590005, 18611154.
23. Shargie E, Lindtjorn B. Determinants of treatment adherence among smear-positive pulmonary tuberculosis patients in Southern Ethiopia. PLoS Med 2007, 4(2):e37. 10.1371/journal.pmed.0040037, 1796905, 17298164.
24. Hasker E, Khodjikhanov M, Usarova S, Asamidinov U, Yuldashova U, Werf M, Uzakova G, Veen J. Default from tuberculosis treatment in Tashkent, Uzbekistan; Who are these defaulters and why do they default?. BMC Infect Dis 2008, 8(1):97. 10.1186/1471-2334-8-97, 2492865, 18647400.
25. Xu W, Lu W, Zhou Y, Zhu L, Shen H, Wang J. Adherence to anti-tuberculosis treatment among pulmonary tuberculosis patients: a qualitative and quantitative study. BMC Health Serv Res 2009, 9(1):169. 10.1186/1472-6963-9-169, 2753329, 19765290.
26. Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. Br Med J 1997, 315(7120):1403-1406.